China's NMPA has approved over 280 AI medical imaging products. Here is how they are being used in hospitals — and what the real-world evidence shows about performance.
China's NMPA has approved more AI medical imaging products than virtually any other regulatory agency globally. As of early 2025, over 280 AI medical imaging products have received NMPA clearance — covering chest CT analysis, coronary CT, X-ray chest disease detection, MRI brain analysis, mammography, fundus photography (diabetic retinopathy), and digital pathology. This breadth of approved products has enabled rapid hospital deployment at a scale that generates substantial real-world outcome data.
The NMPA AI Medical Device Approval Wave
China's NMPA has approved more AI medical imaging products than virtually any other regulatory agency globally. As of early 2025, over 280 AI medical imaging products have received NMPA clearance — covering chest CT analysis, coronary CT, X-ray chest disease detection, MRI brain analysis, mammography, fundus photography (diabetic retinopathy), and digital pathology. This breadth of approved products has enabled rapid hospital deployment at a scale that generates substantial real-world outcome data.
Chest X-Ray AI: Broad Deployment, Published Validation
Chest X-ray interpretation is the highest-volume imaging task in Chinese hospitals, with hundreds of millions of chest radiographs read annually. AI systems from companies including Infervision (ChestLink),推想科技 (Radiology AI), and others have been deployed across hundreds of hospitals to assist with abnormality detection — particularly flagging critical findings that require urgent clinical attention.
Published validation studies across multiple Chinese hospital settings demonstrate that AI chest X-ray tools can reliably detect pneumonia, pleural effusions, and pneumothorax, with published sensitivity and specificity figures that meet or exceed those of junior radiologists in comparable studies. A consistent finding across published literature is that AI assistance is most impactful in after-hours and high-volume settings where radiologist attention may be most stretched.
Coronary CT Angiography: AI-Derived Fractional Flow Reserve
AI-derived fractional flow reserve from CT angiography (CT-FFR) — a non-invasive alternative to catheter-based measurement — represents one of the most clinically mature AI cardiology applications in China. Both HeartFlow's FFRCT (approved in China in 2020) and the domestic competitor Keya Medical's DeepVessel FFR (NMPA-approved) have been evaluated at Chinese cardiac centers.
Fuwai Hospital — China's national cardiac surgery center in Beijing — has integrated AI-FFRCT into its standard pre-operative assessment workflow for elective coronary disease, avoiding unnecessary invasive catheterization in a meaningful proportion of patients who would otherwise proceed to angiography. Published validation data from Chinese sites confirms diagnostic accuracy consistent with international studies.
Diabetic Retinopathy: AI Enabling Community-Level Screening
China has approximately 140 million people with diabetes — the world's largest diabetic population. Diabetic retinopathy is the leading cause of preventable blindness in this group, yet fundus photography screening requires ophthalmologist interpretation unavailable at most community health centers.
AI fundus analysis tools including Airdoc (NMPA-approved for diabetic retinopathy screening) have been deployed across thousands of community health centers in China, enabling immediate screening results without on-site ophthalmologist involvement. Validation studies across multiple Chinese cohorts show sensitivity for referable retinopathy comparable to trained ophthalmologist assessment — directly enabling the timely referral that prevents vision loss.
What International Patients at Chinese Hospitals Experience
Patients attending Class 3A hospitals in Beijing, Shanghai, or other major cities will find AI-assisted radiology integrated as part of the standard workflow. Radiologists at leading institutions use AI platforms as a second reader — not as a replacement for physician judgment. Diagnostic reports are issued by the attending radiologist, who incorporates AI input into their assessment. For international patients, this translates to faster report turnaround and reduced variability in abnormality detection without additional cost.
Sources: NMPA AI medical device approval registry, January 2025; HeartFlow FFRCT China approval documentation 2020; Fuwai Hospital integrated cardiology workflow report; Airdoc NMPA clearance documentation; China Diabetes Society Statistics 2024.